Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfy office msSBP ≥180 mmHg or office msDBP ≥110 mmHg at baseline~Exclusion Criteria:~* Patients show msSBP ≥220 mmHg and/or msDBP ≥120 mmHg~* History of angioedema, drug-related or otherwise, as reported by the patient~* Patients unwilling or not able to discontinue safely the use of current antihypertensive medications during the study, as required by the protocol.~* Patients have significant cardiovascular co-morbidities~* Patients who previously entered a LCZ696 study and had been randomized or enrolled into the active drug treatment epoch.~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 200 mg (Type: EXPERIMENTAL): All participants were started on LCZ696 200 mg once daily on day 1. Participants who achieved mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and for the duration of the study continued at 200 mg LCZ696 once daily.
- LCZ696 400 mg (Type: EXPERIMENTAL): All participants were started on LCZ696 200 mg once daily on day 1. For participants who did not achieve mean sitting diastolic blood pressure (msDBP) of \< 100 mmHg and mean sitting systolic blood pressure (msSBP) of \< 160 mmHg at week 2 or a msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4, and did not have any signs of safety concerns, the LCZ696 dose was increased to 400 mg once daily.
- LCZ696 400 mg plus other hypertension (HTN) medications (Type: EXPERIMENTAL): All participants were started on LCZ696 200 mg once daily on day 1. For participants who received LCZ696 400 mg and did not achieve msDBP \< 90 mmHg and msSBP \< 140 mmHg at or after week 4 and had no signs of safety concerns, another class of antihypertensive drugs (other than Angiotensin II receptor blockers or Angiotensin Converting Enzyme Inhibitor (ACEi) could be added, or the dose of concomitant antihypertensive drugs could be increased as per the package insert. Participants who received LCZ696 400 mg once daily did not change their dose for the remainder of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).